

Everardo D Saad

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9115278/publications.pdf>

Version: 2024-02-01

57
papers

1,665
citations

304368

22
h-index

288905

40
g-index

57
all docs

57
docs citations

57
times ranked

2150
citing authors

#	ARTICLE	IF	CITATIONS
1	Clinical Trial Endpoints in Metastatic Cancer: Using Individual Participant Data to Inform Future Trials Methodology. <i>Journal of the National Cancer Institute</i> , 2022, 114, 819-828.	3.0	2
2	JCOG0603: Are We Really Sure This Was a Negative Trial?. <i>Journal of Clinical Oncology</i> , 2022, 40, 803-805.	0.8	1
3	Surrogacy Beyond Prognosis: The Importance of "Trial-Level" Surrogacy. <i>Oncologist</i> , 2022, 27, 266-271.	1.9	29
4	Considerations on the mechanics and sample sizes for early trials of targeted agents and immunotherapy in oncology. <i>Expert Review of Precision Medicine and Drug Development</i> , 2021, 6, 271-280.	0.4	0
5	Brazilian Validation of the European Organisation for Research and Treatment of Cancer (EORTC) Quality of Life Group (QLG) Computerised Adaptive Tests (CAT) Core. <i>Current Oncology</i> , 2021, 28, 3373-3383.	0.9	1
6	The Net Benefit of a treatment should take the correlation between benefits and harms into account. <i>Journal of Clinical Epidemiology</i> , 2021, 137, 148-158.	2.4	6
7	Commentary on Bamat et al.. <i>Clinical Trials</i> , 2020, 17, 560-561.	0.7	0
8	Statistical Considerations for Trials in Adjuvant Treatment of Colorectal Cancer. <i>Cancers</i> , 2020, 12, 3442.	1.7	2
9	Central statistical monitoring of investigator-led clinical trials in oncology. <i>International Journal of Clinical Oncology</i> , 2020, 25, 1207-1214.	1.0	9
10	Chronological Trends in Progression-Free, Overall, and Post-Progression Survival in First-Line Therapy for Advanced NSCLC. <i>Journal of Thoracic Oncology</i> , 2019, 14, 1619-1627.	0.5	11
11	Evaluation of Continuous Tumor-Size-Based End Points as Surrogates for Overall Survival in Randomized Clinical Trials in Metastatic Colorectal Cancer. <i>JAMA Network Open</i> , 2019, 2, e1911750.	2.8	6
12	Disease-free survival as a surrogate for overall survival in patients with HER2-positive, early breast cancer in trials of adjuvant trastuzumab for up to 1 year: a systematic review and meta-analysis. <i>Lancet Oncology</i> , The, 2019, 20, 361-370.	5.1	59
13	Estudos Brasileiros Apresentados nos Encontros Anuais da ASCO entre 2001 e 2007: Aumento de Produç�o, com Baixa Taxa de Publicaç�o. <i>Revista Brasileira De Cancerologia</i> , 2019, 55, 221-227.	0.0	3
14	Understanding and Communicating Measures of Treatment Effect on Survival: Can We Do Better?. <i>Journal of the National Cancer Institute</i> , 2018, 110, 232-240.	3.0	40
15	Meta-Research on Oncology Trials: A Toolkit for Researchers with Limited Resources. <i>Oncologist</i> , 2018, 23, 1467-1473.	1.9	1
16	Meta-Research in Oncology. , 2018, , 307-314.		0
17	Superiority and Non-inferiority Phase III Oncology Trials. , 2018, , 203-216.		0
18	Precision medicine needs randomized clinical trials. <i>Nature Reviews Clinical Oncology</i> , 2017, 14, 317-323.	12.5	60

#	ARTICLE	IF	CITATIONS
19	Adoption of Pathologic Complete Response as a Surrogate End Point in Neoadjuvant Trials in HER2-Positive Breast Cancer Still an Open Question. <i>JAMA Oncology</i> , 2017, 3, 416.	3.4	4
20	Authors'™ Reply to Schoenfeld: "Progression-Free Survival as a Surrogate for Overall Survival in Clinical Trials of Targeted Therapy in Advanced Solid Tumors" <i>Drugs</i> , 2017, 77, 1139-1140.	4.9	1
21	Progression-Free Survival as a Surrogate for Overall Survival in Clinical Trials of Targeted Therapy in Advanced Solid Tumors. <i>Drugs</i> , 2017, 77, 713-719.	4.9	33
22	Time to Review the Role of Surrogate End Points in Health Policy: State of the Art and the Way Forward. <i>Value in Health</i> , 2017, 20, 487-495.	0.1	101
23	The impact of data errors on the outcome of randomized clinical trials. <i>Clinical Trials</i> , 2017, 14, 499-506.	0.7	15
24	Assessment of quality of life in phase III trials of radiotherapy in localized or locally advanced head and neck cancer over the past 17 years. <i>Annals of Palliative Medicine</i> , 2017, 6, 73-80.	0.5	4
25	Health-related quality of life assessment in contemporary phase III trials in advanced colorectal cancer. <i>Cancer Treatment Reviews</i> , 2016, 50, 194-199.	3.4	9
26	Use of surrogate end points in healthcare policy: a proposal for adoption of a validation framework. <i>Nature Reviews Drug Discovery</i> , 2016, 15, 516-516.	21.5	32
27	Sample Size Calculation in Oncology Trials. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2015, 38, 570-574.	0.6	14
28	Living better or living longer? Perceptions of patients and health care professionals in oncology. <i>Ecancermedalscience</i> , 2015, 9, 574.	0.6	4
29	Meta-analyses of randomized controlled trials show suboptimal validity of surrogate outcomes for overall survival in advanced colorectal cancer. <i>Journal of Clinical Epidemiology</i> , 2015, 68, 833-842.	2.4	48
30	Trial-level association between response-based endpoints (RBEs) and progression-free (PFS)/overall survival (OS) in first-line therapy for metastatic colorectal cancer (mCRC) in the ARCAD database.. <i>Journal of Clinical Oncology</i> , 2015, 33, 666-666.	0.8	1
31	Brazilian Abstracts Presented at the American Urological Association Annual Meetings: Contribution, Publication Rates, and Comparison with Oncology Abstracts. <i>International Braz J Urol: Official Journal of the Brazilian Society of Urology</i> , 2014, 40, 730-737.	0.7	10
32	VALIDATION OF SURROGATE ENDPOINTS IN ADVANCED SOLID TUMORS: SYSTEMATIC REVIEW OF STATISTICAL METHODS, RESULTS, AND IMPLICATIONS FOR POLICY MAKERS. <i>International Journal of Technology Assessment in Health Care</i> , 2014, 30, 312-324.	0.2	69
33	Early predictors of prolonged overall survival (OS) in patients (pts) on first-line chemotherapy (CT) for metastatic colorectal cancer (mCRC): An ARCAD study with individual patient data (IPD) on 10,962 pts.. <i>Journal of Clinical Oncology</i> , 2014, 32, 3538-3538.	0.8	2
34	Early predictors of improved long-term outcomes in first-line antiangiogenics plus chemotherapy (anti-ANG/CT) in metastatic colorectal cancer (mCRC): Analysis of individual patient (pt) data from the ARCAD database.. <i>Journal of Clinical Oncology</i> , 2014, 32, 3578-3578.	0.8	2
35	Treatment priorities in oncology: do we want to live longer or better?. <i>Clinics</i> , 2014, 69, 509-514.	0.6	11
36	Formal Statistical Testing and Inference in Randomized Phase II Trials in Medical Oncology. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2013, 36, 143-145.	0.6	6

#	ARTICLE	IF	CITATIONS
37	Non-inferiority trials in breast and non-small cell lung cancer: Choice of non-inferiority margins and other statistical aspects. <i>Acta Oncol</i> 2012, 51, 890-896.	0.8	25
38	Overall Survival: Patient Outcome, Therapeutic Objective, Clinical Trial End Point, or Public Health Measure?. <i>Journal of Clinical Oncology</i> , 2012, 30, 1750-1754.	0.8	63
39	Assessment of quality of life in advanced breast cancer. An overview of randomized phase III trials. <i>Cancer Treatment Reviews</i> , 2012, 38, 554-558.	3.4	23
40	Assessment of quality of life in advanced non-small-cell lung cancer: An overview of recent randomized trials. <i>Cancer Treatment Reviews</i> , 2012, 38, 807-814.	3.4	25
41	Survival Is Not a Good Outcome for Randomized Trials With Effective Subsequent Therapies. <i>Journal of Clinical Oncology</i> , 2011, 29, 4719-4720.	0.8	33
42	Endpoints in advanced breast cancer: methodological aspects & clinical implications. <i>Indian Journal of Medical Research</i> , 2011, 134, 413-8.	0.4	5
43	Further evidence of the prognostic role of pretreatment levels of CA 19-9 in advanced pancreatic cancer. <i>Revista Da Associação Médica Brasileira</i> , 2010, 56, 22-26.	0.3	3
44	Overall Survival and Post-Progression Survival in Advanced Breast Cancer: A Review of Recent Randomized Clinical Trials. <i>Journal of Clinical Oncology</i> , 2010, 28, 1958-1962.	0.8	148
45	Increasing output and low publication rate of Brazilian studies presented at the American Society of Clinical Oncology Annual Meetings. <i>Clinics</i> , 2008, 63, 293-296.	0.6	12
46	Potential Drug Interactions and Duplicate Prescriptions Among Cancer Patients. <i>Journal of the National Cancer Institute</i> , 2007, 99, 592-600.	3.0	279
47	A Systematic Review on Drug Interactions in Oncology. <i>Cancer Investigation</i> , 2006, 24, 704-712.	0.6	49
48	Potential for drug interactions in hospitalized cancer patients. <i>Cancer Chemotherapy and Pharmacology</i> , 2005, 56, 286-290.	1.1	132
49	Chemotherapy of metastatic colorectal cancer. <i>Current Treatment Options in Gastroenterology</i> , 2005, 8, 239-247.	0.3	9
50	Molecular-Targeted Agents in Pancreatic Cancer. <i>Cancer Control</i> , 2004, 11, 32-38.	0.7	24
51	UFT and Oral Leucovorin as Radiation Sensitizers in Rectal and Other Gastrointestinal Malignancies. <i>Cancer Investigation</i> , 2003, 21, 624-629.	0.6	4
52	Targeted drugs in oncology: New names, new mechanisms, new paradigm. <i>American Journal of Health-System Pharmacy</i> , 2003, 60, 1233-1243.	0.5	6
53	Phase II Study of Dolastatin-10 as First-Line Treatment for Advanced Colorectal Cancer. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2002, 25, 451-453.	0.6	61
54	Incidence and Severity of Hand-Foot Syndrome in Colorectal Cancer Patients Treated with Capecitabine: A Single-Institution Experience. <i>Cancer Investigation</i> , 2002, 20, 3-10.	0.6	93

#	ARTICLE	IF	CITATIONS
55	Prognostic stratification in UPC: a role for assessing the value of conventional-dose and high-dose chemotherapy for unknown primary carcinoma. <i>Critical Reviews in Oncology/Hematology</i> , 2002, 41, 205-211.	2.0	6
56	Case Report: Hand-Foot Syndrome Induced by the Oral Fluoropyrimidine S-1. <i>Japanese Journal of Clinical Oncology</i> , 2001, 31, 172-174.	0.6	12
57	Phase I Study of Preoperative Oral Uracil and Tegafur Plus Leucovorin and Radiation Therapy in Rectal Cancer. <i>Journal of Clinical Oncology</i> , 2000, 18, 3529-3534.	0.8	57